drugset
drugset / Trial / NCT02284971

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

NCT02284971 ↗

Phase 1 Terminated 2 enrolled James Larner, MD Celldex Therapeutics · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the combination of stereotactic body radiation therapy (SBRT) and CDX-1127 in subjects with castration resistant prostate cancer. Subjects will be randomized to one of three arms to receive SBRT prior to, after, or in conjunction with the first dose of CDX-1127.

Timeline

Start
2014-11
Primary completion
2016-04-07
Completion
2016-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Varlilumab Monoclonal antibody 3 mg/kg Intravenous

Indications

prostate cancer